This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wong, C. M. Articles by Ng, I. O. L. Search for Related Content PubMed PubMed Citation Articles by Wong, C. M. Articles by Ng, I. O. L.

Clinicopathological Significance of Loss of Heterozygosity on Chromosome 13q in Hepatocellular Carcinoma¹

Departments of Pathology [C. M. W., J. M. F. L., T. C. M. L., I. O. L. N.] and Surgery [S. T. F.] University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong

Purpose: Allelic loss is the most frequently genetic alteration found in hepatocellular carcinoma (HCC). Previous genome-wide studies have indicated that chromosome 13q is one of the most frequently affected chromosomes. However, reports on detailed deletion mapping as well as detailed clinicopathological correlation are scanty.

Experimental Design: We performed high-density allelotyping on chromosome 13q in HCC from 60 patients and investigated the correlation between allelic losses on chromosome 13q and the clinicopathological features.

Results: Allelic loss at one or more of the 29 microsatellite markers was found in 28 (47%) of the 60 HCCs. Allelic losses were more frequently found in tumors with larger size or in tumors at more advanced tumor stages (P = 0.015 and 0.012, respectively). These two clinicopathological features were also significantly associated with the accumulation of allelic losses in terms of fractional allelic loss index (P = 0.028 and 0.018, respectively). In addition, subchromosomal regions located at 13q12.3-14.1 and 13q32 were found to be significantly associated with advanced tumor stages and larger tumor size, respectively (P = 0.008 and 0.007).

Conclusions: The overall findings suggested that allelic losses on 13q might play an important role in contributing to a more aggressive tumor behavior. Putative tumor suppressor genes might be harbored at 13q12.3-14.1 and 13q32, and inactivation of these genes via allelic losses might enhance tumor progression in HCC.

This article has been cited by other articles:

				J.-Z. Pang, L.-X. Qin, N. Ren, Z.-Y. Hei, Q.-H. Ye, W.-D. Jia, B.-S. Sun, G.-L. Lin, D.-Y. Liu, Y.-K. Liu, et al. Loss of Heterozygosity at D8S298 Is a Predictor for Long-term Survival of Patients with Tumor-Node-Metastasis Stage I of Hepatocellular Carcinoma Clin. Cancer Res., December 15, 2007; 13(24): 7363 - 7369. [Abstract] [Full Text] [PDF]

				C.-M. Wong, J. W.-P. Yam, Y.-P. Ching, T.-O. Yau, T. H.-Y. Leung, D.-Y. Jin, and I. O.-L. Ng Rho GTPase-Activating Protein Deleted in Liver Cancer Suppresses Cell Proliferation and Invasion in Hepatocellular Carcinoma Cancer Res., October 1, 2005; 65(19): 8861 - 8868. [Abstract] [Full Text] [PDF]

				Y. Midorikawa, S. Tsutsumi, K. Nishimura, N. Kamimura, M. Kano, H. Sakamoto, M. Makuuchi, and H. Aburatani Distinct Chromosomal Bias of Gene Expression Signatures in the Progression of Hepatocellular Carcinoma Cancer Res., October 15, 2004; 64(20): 7263 - 7270. [Abstract] [Full Text] [PDF]

				C.-M. Wong, J. M.-F. Lee, Y.-P. Ching, D.-Y. Jin, and I. O.-l. Ng Genetic and Epigenetic Alterations of DLC-1 Gene in Hepatocellular Carcinoma Cancer Res., November 15, 2003; 63(22): 7646 - 7651. [Abstract] [Full Text] [PDF]

				Y.-P. Ching, C.-M. Wong, S.-F. Chan, T. H.-Y. Leung, D. C.-H. Ng, D.-Y. Jin, and I. O.-l. Ng Deleted in Liver Cancer (DLC) 2 Encodes a RhoGAP Protein with Growth Suppressor Function and Is Underexpressed in Hepatocellular Carcinoma J. Biol. Chem., March 14, 2003; 278(12): 10824 - 10830. [Abstract] [Full Text] [PDF]